{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:00:32Z","timestamp":1758632432851},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T00:00:00Z","timestamp":1397779200000},"content-version":"vor","delay-in-days":352,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.jmoldx.2013.02.004","type":"journal-article","created":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T09:15:47Z","timestamp":1364375747000},"page":"391-400","source":"Crossref","is-referenced-by-count":9,"title":["Quality Control Methods for Optimal BCR-ABL1 Clinical Testing in Human Whole Blood Samples"],"prefix":"10.1016","volume":"15","author":[{"given":"Lauren M.","family":"Stanoszek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin L.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Blomquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Warns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige F.S.","family":"Willey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Willey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2013.02.004_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib2","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V81.1.158.158","article-title":"The ABL-BCR fusion gene is expressed in chronic myeloid leukemia","volume":"81","author":"Melo","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A\u00a0cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia","volume":"300","author":"de Klein","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib8","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib9","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate: a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib12","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib14","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1586\/ehm.10.61","article-title":"Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study","volume":"3","author":"Giles","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib18","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.jmoldx.2013.02.004_bib19","doi-asserted-by":"crossref","first-page":"S391","DOI":"10.3816\/CLM.2009.s.039","article-title":"Molecular monitoring of patients with chronic myeloid leukemia: clinical examples from a non-trial setting","volume":"9","author":"Radich","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"Suppl 4","key":"10.1016\/j.jmoldx.2013.02.004_bib20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0077","article-title":"NCCN task force report: molecular markers in leukemias and lymphomas","volume":"7","author":"Radich","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.beha.2009.04.002","article-title":"The impact of gene profiling in chronic myeloid leukaemia","volume":"22","author":"Yong","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib22","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib23","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0140-6736(89)92508-7","article-title":"Polymerase chain reaction for detection of residual leukaemia","volume":"1","author":"Morgan","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib24","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/sj.leu.2401899","article-title":"Quality assurance in RT-PCR-based BCR\/ABL diagnostics: results of an interlaboratory test and a standardization approach","volume":"14","author":"Burmeister","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2353\/jmoldx.2007.060134","article-title":"Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations","volume":"9","author":"Zhang","year":"2007","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1620\/tjem.214.97","article-title":"Interlaboratory comparison of quantitative RT-PCR based detection for minimal residual disease in leukemias: a standardization approach in Japan","volume":"214","author":"Yamada","year":"2008","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib27","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3324\/haematol.11172","article-title":"An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR","volume":"92","author":"Muller","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.beha.2009.04.001","article-title":"Standardisation of molecular monitoring for chronic myeloid leukaemia","volume":"22","author":"Cross","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib29","first-page":"1099","article-title":"Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples","volume":"28","author":"Stock","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib31","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib32","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","author":"White","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1520\/JFS13607J","article-title":"Identification of the heme compound copurified with deoxyribonucleic acid (DNA) from bloodstains, a major inhibitor of polymerase chain reaction (PCR) amplification","volume":"39","author":"Akane","year":"1994","journal-title":"J Forensic Sci"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib34","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1128\/JCM.39.2.485-493.2001","article-title":"Purification and characterization of PCR-inhibitory components in blood cells","volume":"39","author":"Al-Soud","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0168-1605(92)90017-W","article-title":"Inhibition of PCR by components of food samples, microbial diagnostic assays and DNA-extraction solutions","volume":"17","author":"Rossen","year":"1992","journal-title":"Int J Food Microbiol"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib36","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1093\/nar\/19.21.6051","article-title":"Detection of gene expression by PCR amplification of RNA derived from frozen heparinized whole blood","volume":"19","author":"Izraeli","year":"1991","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib37","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1128\/JCM.36.9.2443-2446.1998","article-title":"Strategy for optimizing DNA amplification in a peripheral blood PCR assay used for diagnosis of human brucellosis","volume":"36","author":"Morata","year":"1998","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib38","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1152\/physiolgenomics.00020.2004","article-title":"Whole blood and leukocyte RNA isolation for gene expression analyses","volume":"19","author":"Feezor","year":"2004","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib39","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2353\/jmoldx.2006.060021","article-title":"Effects of globin mRNA reduction methods on gene expression profiles from whole blood","volume":"8","author":"Liu","year":"2006","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/14737159.5.1.43","article-title":"Gene expression profiling using RNA extracted from whole blood: technologies and clinical applications","volume":"5","author":"Pahl","year":"2005","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib41","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2257.2002.00474.x","article-title":"Substantial changes in gene expression level due to the storage temperature and storage duration of human whole blood","volume":"24","author":"Tanner","year":"2002","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib42","series-title":"BCR-ABL p210 Survey Participant Summary","author":"MRD","year":"2011"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib43","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nmeth1005-731","article-title":"The External RNA Controls Consortium: a progress report","volume":"2","author":"Baker","year":"2005","journal-title":"Nat Methods"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib44","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2164-6-150","article-title":"Controls Consortium. Proposed methods for testing and selecting the ERCC external RNA controls","volume":"6","author":"External","year":"2005","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib45","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2164-12-118","article-title":"Applicability of RNA standards for evaluating RT-qPCR assays and platforms","volume":"12","author":"Devonshire","year":"2011","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib46","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/bioinformatics\/btm404","article-title":"Clustal W.and Clustal X. version 2.0","volume":"23","author":"Larkin","year":"2007","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib47","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u201creal-time\u201d quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2353\/jmoldx.2006.040404","article-title":"Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts","volume":"8","author":"Wang","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib49","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2353\/jmoldx.2006.050150","article-title":"beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia","volume":"8","author":"Lee","year":"2006","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib50","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/nar\/21.4.1047","article-title":"A rapid and versatile method to synthesize internal standards for competitive PCR","volume":"21","author":"Celi","year":"1993","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib51","first-page":"13","article-title":"Standardized RT-PCR and the standardized expression measurement center","volume":"258","author":"Willey","year":"2004","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib52","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/sj.leu.2403309","article-title":"Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease: a study within the Europe Against Cancer Program","volume":"18","author":"van der Velden","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib53","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.leukres.2011.03.022","article-title":"Effect of the duration and quality of peripheral blood sample storage on the results of qualitative and quantitative BCR-ABL transcript analyses in patients with CML","volume":"35","author":"Moravcova","year":"2011","journal-title":"Leuk Res"},{"issue":"Pt 2","key":"10.1016\/j.jmoldx.2013.02.004_bib54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/bj3370231","article-title":"Differential priming of RNA templates during cDNA synthesis markedly affects both accuracy and reproducibility of quantitative competitive reverse-transcriptase PCR","volume":"337","author":"Zhang","year":"1999","journal-title":"Biochem J"},{"key":"10.1016\/j.jmoldx.2013.02.004_bib55","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1373\/clinchem.2008.105916","article-title":"Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease","volume":"54","author":"Ross","year":"2008","journal-title":"Clin Chem"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157813000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157813000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T12:04:48Z","timestamp":1595592288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157813000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1525157813000433"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2013.02.004","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}